EE398 Cost Comparison of Osimertinib Plus Chemotherapy Versus Amivantamab Plus Lazertinib for the First-Line Treatment of Patients With Locally Advanced or Metastatic EGFR-Mutated NSCLC
Abstract
Authors
Harry Freeman Elysia Upton Pritesh S. Karia Yanique Rattigan-Brown Natalie Hearmon Emily Procter Jorge J. Nieva